-
Antidepressants Differ Significantly in Cardiometabolic Side Effects
23 Oct 2025 01:36 GMT
… & Drug Administration (FDA) website from … controlled trials (RCTs) comparing antidepressants … , doxepin, levomilnacipran, reboxetine, desvenlafaxine, venlafaxine, and … Antidepressant monotherapy: A claims database analysis of treatment changes and treatment …
-
<![CDATA[Antidepressants Differ Significantly in Cardiometabolic Side Effects ]]>
23 Oct 2025 00:52 GMT
… US Food & Drug Administration (FDA) website from database … randomized controlled trials (RCTs) comparing antidepressants and placebo … antidepressants with placebo. RCTs had a median treatment duration … ), phenelzine (n=1), reboxetine (n=5), selegiline (n …
-
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
03 Nov 2025 12:00 GMT
… commercial and government (Medicare and Medicaid) channels are approximately … 3 trial in 2026.
AXS-12 AXS-12 (reboxetine) is … treatment of narcolepsy. AXS-12 has been granted FDA Orphan Drug … ongoing clinical trials and anticipated clinical trials for the …
-
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
09 Jun 2025 11:00 GMT
… this important investigational medicine for the approximately … reboxetine. AXS-14 is an investigational drug product not approved by the FDA … portfolio includes FDA-approved treatments for major … clinical trials and anticipated clinical trials for …
-
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
11 Jun 2025 11:00 GMT
… Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology … AXS-12 AXS-12 (reboxetine) is a highly … Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of … ongoing clinical trials and anticipated clinical trials for the …
-
Axsome plots new fibromyalgia trial after FDA refuses to review former Pfizer candidate
09 Jun 2025 21:05 GMT
… their primary endpoints.
Both trials were conducted by Pfizer. … the FDA’s Division of Anesthesiology, Addiction Medicine and Pain Medicine … to the New York biotech’s first quarter earnings … revitalize reboxetine, called AXS-12 at Axsome, as a treatment for …
-
Pharmacological properties of antidepressants
09 Jun 2025 00:06 GMT
Pharmacological properties of antidepressants30-49
Drug class (mode … exhaustive list)29*
Drug
Half-life
Selective … sexual dysfunction
Reboxetine
13 hrs
Tricyclic Antidepressants (TCAs)
Both … medicines.ie for more detailed information on side effects and drug …
-
Switching Antidepressants
08 Jun 2025 20:03 GMT
… guide for switching antidepressants (all antidepressant switches must be … Stop agomelatine, then start reboxetine
Stop agomelatine, then start … SPCs available on www.medicines.ie for more detailed … Fluoxetine may still cause drug interactions 5 weeks after …
-
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
04 Apr 2025 11:00 GMT
… antidepressant medicines called SSRIs or SNRIs. Stop taking SYMBRAVO and call your doctor … -12 AXS-12 (reboxetine) is a highly … and Drug Administration (FDA) Orphan Drug Designation for the treatment of … clinical trials and anticipated clinical trials for …
-
Axsome Therapeutics to present positive phase 3 results of ACCORD─2 trial of AXS─05 in AD agitation and SYMPHONY trial of AXS─12 in narcolepsy at the 2025 AAN meeting
07 Apr 2025 13:00 GMT
… pivotal SYMPHONY phase 3 trial of AXS-12 in … Medicine, New York, NY -- Session Name: Clinical Trials … treatment of Alzheimer’s disease agitation in June 2020.
AXS-12 (reboxetine … Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of …
About
© 1995-2025